BR112012027463A2 - método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit - Google Patents
método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kitInfo
- Publication number
- BR112012027463A2 BR112012027463A2 BR112012027463A BR112012027463A BR112012027463A2 BR 112012027463 A2 BR112012027463 A2 BR 112012027463A2 BR 112012027463 A BR112012027463 A BR 112012027463A BR 112012027463 A BR112012027463 A BR 112012027463A BR 112012027463 A2 BR112012027463 A2 BR 112012027463A2
- Authority
- BR
- Brazil
- Prior art keywords
- triiodothyronine
- biochemical
- kit
- pharmaceutical composition
- therapeutic method
- Prior art date
Links
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229940043671 antithyroid preparations Drugs 0.000 abstract 3
- 239000003200 antithyroid agent Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003208 anti-thyroid effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32882510P | 2010-04-28 | 2010-04-28 | |
| PCT/IL2011/000346 WO2011135574A1 (en) | 2010-04-28 | 2011-04-28 | Methods, compositions and kits for providing a therapeutic treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012027463A2 true BR112012027463A2 (pt) | 2015-09-29 |
Family
ID=44860959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012027463A BR112012027463A2 (pt) | 2010-04-28 | 2011-04-28 | método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9655984B2 (enExample) |
| EP (1) | EP2563120B1 (enExample) |
| JP (1) | JP5921529B2 (enExample) |
| KR (1) | KR101841304B1 (enExample) |
| CN (1) | CN102858156B (enExample) |
| AU (1) | AU2011246851B2 (enExample) |
| BR (1) | BR112012027463A2 (enExample) |
| CA (1) | CA2797625C (enExample) |
| ES (1) | ES2791708T3 (enExample) |
| MX (1) | MX2012012479A (enExample) |
| WO (1) | WO2011135574A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386702B (es) | 2014-02-10 | 2025-03-19 | Fred Hutchinson Cancer Center | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. |
| CN105486869A (zh) * | 2014-10-08 | 2016-04-13 | 江苏维赛科技生物发展有限公司 | 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用 |
| US20200222348A1 (en) * | 2017-05-08 | 2020-07-16 | Musli Thyropeutics Ltd. | Bimodal modified release compositions for cancer treatment |
| WO2021257806A1 (en) * | 2020-06-18 | 2021-12-23 | Fred Hutchinson Cancer Research Center | Iodide for treatment of nonthyroidal illness syndrome |
| CN114605278A (zh) * | 2022-02-11 | 2022-06-10 | 天津市肿瘤医院（天津医科大学肿瘤医院） | T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用 |
| CN114878840A (zh) * | 2022-07-12 | 2022-08-09 | 昆明思安生物科技有限公司 | 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB851610A (en) | 1956-03-07 | 1960-10-19 | Gunther Hillman | Method for producing iodine derivatives of thyronine |
| US4426453A (en) | 1980-09-18 | 1984-01-17 | Amersham International Limited | Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds |
| JPH07116031B2 (ja) | 1986-09-24 | 1995-12-13 | 株式会社アドバンス | 制癌剤 |
| US6017958A (en) | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| AU7721500A (en) | 1999-09-29 | 2001-04-30 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US6939863B2 (en) * | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
| US7074426B2 (en) * | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| JP2009507847A (ja) * | 2005-09-08 | 2009-02-26 | シャイア エルエルシー | 生体利用性を増強したｔ３及びｔ４のプロドラッグ |
-
2011
- 2011-04-28 CA CA2797625A patent/CA2797625C/en not_active Expired - Fee Related
- 2011-04-28 JP JP2013506810A patent/JP5921529B2/ja not_active Expired - Fee Related
- 2011-04-28 EP EP11774538.0A patent/EP2563120B1/en active Active
- 2011-04-28 CN CN201180020423.4A patent/CN102858156B/zh not_active Expired - Fee Related
- 2011-04-28 ES ES11774538T patent/ES2791708T3/es active Active
- 2011-04-28 MX MX2012012479A patent/MX2012012479A/es not_active Application Discontinuation
- 2011-04-28 AU AU2011246851A patent/AU2011246851B2/en not_active Ceased
- 2011-04-28 BR BR112012027463A patent/BR112012027463A2/pt not_active Application Discontinuation
- 2011-04-28 US US13/643,907 patent/US9655984B2/en not_active Expired - Fee Related
- 2011-04-28 WO PCT/IL2011/000346 patent/WO2011135574A1/en not_active Ceased
- 2011-04-28 KR KR1020127030962A patent/KR101841304B1/ko not_active Expired - Fee Related
-
2017
- 2017-04-11 US US15/484,691 patent/US10398789B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011246851A1 (en) | 2012-11-15 |
| MX2012012479A (es) | 2013-07-03 |
| EP2563120A4 (en) | 2015-05-13 |
| EP2563120A1 (en) | 2013-03-06 |
| US20170274104A1 (en) | 2017-09-28 |
| EP2563120B1 (en) | 2020-02-26 |
| JP5921529B2 (ja) | 2016-05-24 |
| CA2797625A1 (en) | 2011-11-03 |
| US10398789B2 (en) | 2019-09-03 |
| AU2011246851B2 (en) | 2016-07-21 |
| KR20130103336A (ko) | 2013-09-23 |
| JP2013525422A (ja) | 2013-06-20 |
| US9655984B2 (en) | 2017-05-23 |
| ES2791708T3 (es) | 2020-11-05 |
| US20130129615A1 (en) | 2013-05-23 |
| CA2797625C (en) | 2019-08-20 |
| CN102858156B (zh) | 2015-09-23 |
| WO2011135574A1 (en) | 2011-11-03 |
| KR101841304B1 (ko) | 2018-03-22 |
| CN102858156A (zh) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012020304A2 (pt) | complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
| UY31073A1 (es) | Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap) | |
| BRPI0611717A2 (pt) | composto, composiÇço farmacÊutica e uso do composto | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112012027463A2 (pt) | método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112015027288A8 (pt) | uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| IN2015DN00376A (enExample) | ||
| BR112016013832A2 (pt) | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico | |
| BR112013015786A2 (pt) | composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| BR112016021034A8 (pt) | composição farmacêutica, uso da mesma e kit | |
| BR112015017241A8 (pt) | composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit | |
| BRPI0915439B8 (pt) | composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição | |
| BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |